Britain's medicines regulator said on Friday it had made the world's largest seizure of unlicensed weight-loss medicines, ...

U.S. pharmaceutical giant Eli Lilly (LLY) is acquiring gene therapy developer Adverum Biotechnologies (ADVM) in a deal valued ...

Relay Therapeutics, Inc. leads with RLY-2608, an allosteric PI3Kα inhibitor showing superior safety & efficacy. Learn more ...

"UK regulators seize illegal weight loss drugs amid global pricing shake-up" was originally created and published by ...

"Lilly and Incyte to seek approval of alopecia JAK inhibitor in children" was originally created and published by ...

Sometimes the biggest moments at a conference happen backstage. At the annual STAT Summit, that kind of moment involved a ...

See, LLY stock warrants your attention. Why? Because it offers monopoly-like high margins at a discounted price.

Just as Adverum’s cash reserves were running dry, Eli Lilly has swooped in to buy the biotech and its phase 3-stage eye disease gene therapy.

Eli Lilly said on Friday it would acquire gene therapy developer Adverum Biotechnologies in a deal valued at up to $261.7 ...

A major boardroom shake-up at Novo Nordisk has given the Novo Nordisk Foundation an unprecedented level of control, raising ...

Eli Lilly said Friday it is set to acquire clinical-stage company Adverum Biotechnologies for up to $12.47 a share, including milestone payments.